Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.71 - $17.11 $625,464 - $999,224
58,400 Added 36.64%
217,800 $2.75 Million
Q2 2024

Aug 14, 2024

BUY
$3.89 - $20.97 $322,481 - $1.74 Million
82,900 Added 108.37%
159,400 $2.02 Million
Q1 2024

May 15, 2024

BUY
$3.76 - $6.02 $287,640 - $460,529
76,500 New
76,500 $365,000
Q3 2023

Nov 15, 2023

BUY
$6.81 - $9.74 $1.45 Million - $2.08 Million
213,200 New
213,200 $1.54 Million
Q1 2023

May 15, 2023

SELL
$5.76 - $12.48 $720,576 - $1.56 Million
-125,100 Reduced 48.1%
135,000 $890,000
Q4 2022

Feb 14, 2023

BUY
$8.86 - $25.04 $2.3 Million - $6.51 Million
260,100 New
260,100 $2.67 Million
Q2 2022

Aug 15, 2022

SELL
$36.28 - $75.29 $145,120 - $301,160
-4,000 Reduced 2.97%
130,900 $6.79 Million
Q1 2022

May 16, 2022

SELL
$69.73 - $142.9 $3.78 Million - $7.75 Million
-54,200 Reduced 28.66%
134,900 $10.1 Million
Q4 2021

Feb 14, 2022

SELL
$134.56 - $217.97 $4.7 Million - $7.61 Million
-34,900 Reduced 15.58%
189,100 $29.3 Million
Q3 2021

Nov 12, 2021

SELL
$177.8 - $270.58 $1.28 Million - $1.95 Million
-7,200 Reduced 3.11%
224,000 $45.6 Million
Q2 2021

Aug 06, 2021

BUY
$121.0 - $257.67 $4.71 Million - $10 Million
38,900 Added 20.23%
231,200 $48.3 Million
Q1 2021

May 14, 2021

BUY
$112.98 - $319.93 $2.71 Million - $7.68 Million
24,000 Added 14.26%
192,300 $33.3 Million
Q4 2020

Feb 12, 2021

BUY
$78.74 - $139.5 $692,912 - $1.23 Million
8,800 Added 5.52%
168,300 $20 Million
Q3 2020

Nov 13, 2020

BUY
$79.44 - $178.51 $5.25 Million - $11.8 Million
66,100 Added 70.77%
159,500 $17.2 Million
Q2 2020

Aug 13, 2020

SELL
$13.86 - $83.61 $261,954 - $1.58 Million
-18,900 Reduced 16.83%
93,400 $7.81 Million
Q1 2020

May 11, 2020

BUY
$3.93 - $16.0 $441,339 - $1.8 Million
112,300 New
112,300 $1.61 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $630M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.